Austrianova announces the publication of a peer-reviewed article on the use of implanted Cell-in-a-Box encapsulated cells for the sustained production of the anti-aging protein Klotho in patients

by Walter Gunzburg | Oct 31, 2026 | Press Release

Brian Salmons, Austrianova’s CEO added “This publication provides the background and future perspectives for our ongoing collaboration with Avaí Bio through our joint venture company, Klothonova.  This press release can be viewed online...

Avaí Bio and Austrianova Hold First Joint Steering Committee Meeting with Ospedale SanRaffaele for Diabetes Cell Therapy Program

by Walter Gunzburg | Oct 8, 2026 | News, Press Release

This press release can be viewed online at: https://www.globenewswire.com/news-release/2026/10/07   LAS VEGAS, NEVADA, Oct. 07, 2026 (GLOBE NEWSWIRE) — Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and its joint venture partner Austrianova, today...

Avaí Bio and Austrianova Present Encapsulated Cell Approach to Sustained α-Klotho Delivery at 2026 Klotho Conference

by Walter Gunzburg | Sep 26, 2026 | News, Press Release

This press release can be viewed online at: https://ir.avaibio.com/press-releases/2026/avai-bio-and-austrianova-present-encapsulated-cell-approach-to-sustained-klotho-delivery-at-2026-klotho-conference Watch Austrianova Founder & CTO, Prof. Walter Gunzburg...

Avaí Bio and Austrianova Announce Research Collaboration with San Raffaele Hospital to Advance Encapsulated Cell Therapy for Diabetes

by Walter Gunzburg | Aug 13, 2026 | Press Release

This press release can be viewed online at: https://www.globenewswire.com/news-release/2026/08/12/3343647https://www.einpresswire.com/article/634030792/ Agreement combines Austrianova’s Cell-in-a-Box® technology with San Raffaele Hospital’s stem cell-derived beta cell...

Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy

by Walter Gunzburg | May 21, 2026 | News

LAS VEGAS, May 20, 2026 /PRNewswire/ — Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today...